|
1
|
Gomaa AI, Khan SA, Toledano MB, Waked I
and Taylor-Robinson SD: Hepatocellular carcinoma: Epidemiology,
risk factors and pathogenesis. World J Gastroenterol. 14:4300–4308.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kudo M: Early detection and curative
treatment of early-stage hepatocellular carcinoma. Clin
Gastroenterol Hepatol. 3:S144–S148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
4
|
Lencioni R: Surveillance and early
diagnosis of hepatocellular carcinoma. Dig Liver Dis. 42:S223–S227.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang BH, Yang BH and Tang ZY: Randomized
controlled trial of screening for hepatocellular carcinoma. J
Cancer Res Clin Oncol. 130:417–422. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong LL, Limm WM, Severino R and Wong LM:
Improved survival with screening for hepatocellular carcinoma.
Liver Transpl. 6:320–325. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Daniele B, Bencivenga A, Megna AS and
Tinessa V: α-fetoprotein and ultrasonography screening for
hepatocellular carcinoma. Gastroenterology. 127:S108–S112.
2004.
|
|
8
|
Tan EM: Autoantibodies as reporters
identifying aberrant cellular mechanisms in tumorigenesis. J Clin
Invest. 108:1411–1415. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tan EM and Zhang JY: Autoantibodies to
tumor-associated antigens: reporters from the immune system.
Immunol Rev. 222:328–340. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang JY and Tan EM: Autoantibodies to
tumor-associated antigens as diagnostic biomarkers in
hepatocellular carcinoma and other solid tumors. Expert Rev Mol
Diagn. 10:321–328. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang JY: Mini-array of multiple
tumor-associated antigens to enhance autoantibody detection for
immunodiagnosis of hepatocellular carcinoma. Autoimmun Rev.
6:143–148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Y, Zhou YS, Qiu SM, Wang KJ, Liu SW,
Peng XX, Li JF, et al: Autoantibodies to tumor-associated antigens
combined with abnormal alpha-fetoprotein enhance immunodiagnosis of
hepatocellular carcinoma. Cancer Lett. 289:32–39. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee AS: The glucose-regulated proteins:
stress induction and clinical applications. Trends Biochem Sci.
26:504–510. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee AS: GRP78 induction in cancer:
therapeutic and prognostic implications. Cancer Res. 67:3496–3499.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hendershot LM: The ER function BiP is a
master regulator of ER function. Mt Sinai J Med. 71:289–297.
2004.PubMed/NCBI
|
|
16
|
Uramoto H, Sugio K, Oyama T, Nakata S, Ono
K, Yoshimastu T, Morita M, et al: Expression of endoplasmic
reticulum molecular chaperone Grp78 in human lung cancer and its
clinical significance. Lung Cancer. 49:55–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fernandez PM, Tabbara SO, Jacobs LK,
Manning FC, Tsangaris TN, Schwartz AM, Kennedy KA, et al:
Overexpression of the glucose-regulated stress gene GRP78 in
malignant but not benign human breast lesions. Breast Cancer Res
Treat. 59:15–26. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng HC, Takahashi H, Li XH, Hara T,
Masuda S, Guan YF and Takano Y: Overexpression of GRP78 and GRP94
are markers for aggressive behavior and poor prognosis in gastric
carcinomas. Hum Pathol. 39:1042–1049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pootrakul L, Datar RH, Shi SR, Cai J,
Hawes D, Groshen SG, Lee AS, et al: Expression of stress response
protein GRP78 is associated with the development of
castration-resistant prostate cancer. Clin Cancer Res.
12:5987–5993. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luk JM, Lam CT, Siu AFM, Lam BY, Ng IOL,
Hu MY, Che CM, et al: Proteomic profiling of hepatocellular
carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27,
Hsp70, GRP78) up-regulation and their associated prognostic values.
Proteomics. 6:1049–1057. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong DZ, Ni M, Li JZ, Xiong SG, Ye W,
Virrey JJ, Mao CH, et al: Critical role of the stress chaperone
GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis
in transgene-induced mammary tumor development. Cancer Res.
68:498–505. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Daneshmand S, Quek ML, Lin E, Lee C, Cote
RJ, Hawes D, Cai J, et al: Glucose-regulated protein GRP78 is
up-regulated in prostate cancer and correlates with recurrence and
survival. Hum Pathol. 38:1547–1552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su RJ, Li Z, Li HD, Song HJ, Bao CF, Wei J
and Cheng LF: Grp78 promotes the invasion of hepatocellular
carcinoma. BMC Cancer. 10:202010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong DZ, Stapleton C, Luo BQ, Xiong SG, Ye
W, Zhang Y, Jhaveri N, et al: A critical role for GRP78/BiP in the
tumor microenvironment for neovascularization during tumor growth
and metastasis. Cancer Res. 71:2848–2857. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Katanasaka Y, Ishii T, Asai T, Naitou H,
Maeda N, Koizumi F, Miyagawa S, et al: Cancer antineovascular
therapy with liposome drug delivery systems targeted to BiP/GRP78.
Int J Cancer. 127:2685–2698. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sugawara S, Takeda K, Lee A and Dennert G:
Suppression of stress protein GRP78 induction in tumor B/C10ME
eliminates resistance to cell mediated cytotoxicity. Cancer Res.
53:6001–6005. 1993.PubMed/NCBI
|
|
27
|
Chiou JF, Tai CJ, Huang MT, Wei PL, Wang
YH, BS JA, Wu CH, et al: Glucose-regulated protein 78 is a novel
contributor to acquisition of resistance to sorafenib in
hepatocellular carcinoma. Ann Surg Oncol. 17:603–612. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Berger CL, Dong ZM, Hanlon D, Bisaccia E
and Edelson RL: A lymphocyte cell surface heat shock protein
homologous to the endoplasmic reticulum chaperone, immunoglobulin
heavy chain binding protein BIP. Int J Cancer. 71:1077–1085. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin BK, Wang H, Yim AM, Naour FL,
Brichory F, Jang JH, Zhao R, et al: Global profiling of the cell
surface proteome of cancer cells uncovers an abundance of proteins
with chaperone function. J Biol Chem. 278:7607–7616. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arap MA, Lahdenranta J, Mintz PJ, Hajitou
A, Sarkis AS, Arap W and Pasqualini R: Cell surface expression of
the stress response chaperone GRP78 enables tumor targeting by
circulating ligands. Cancer Cell. 6:275–284. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mintz PJ, Kim J, Do KA, Wang XM, Zinner
RG, Cristofanilli M, Arap MA, et al: Fingerprinting the circulating
repertoire of antibodies from cancer patients. Nat Biotechnol.
21:57–63. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gonzalez-Gronow M, Cuchacovich M, Llanos
C, Urzua C, Gawdi G and Pizzo SV: Prostate cancer cell
proliferation in vitro is modulated by antibodies against
glucose-regulated protein 78 isolated from patient serum. Cancer
Res. 66:11424–11431. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsunemi S, Nakanishi T, Fujita Y, Bouras
G, Miyamoto Y, MiyamotoI A, Nomura E, et al: Proteomics-based
identification of a tumor-associated antigen and its corresponding
autoantibody in gastric cancer. Oncol Rep. 23:949–956.
2010.PubMed/NCBI
|
|
34
|
Johnson PJ, Leung N, Cheng P, Welby C,
Leung WT, Lau WY, Yu S and Ho S: ‘Hepatoma-specific’
alphafetoprotein may permit preclinical diagnosis of malignant
change in patients with chronic liver disease. Br J Cancer.
75:236–240. 1997.
|
|
35
|
Gordis L: Assessing the validity and
reliability of diagnostic and screening tests. Epidemiology. 2nd
edition. W.B. Saunders Company; Philadelphia, PA: pp. 63–81.
2000
|
|
36
|
Kaufman RJ: Orchestrating the unfolded
protein response in health and disease. J Clin Invest.
110:1389–1398. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ni M and Lee AS: ER chaperones in
mammalian development and human diseases. FEBS Lett. 581:3641–3651.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pfaffenbach KT and Lee AS: The critical
role of GRP78 in physiologic and pathologic stress. Curr Opin Cell
Biol. 23:150–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lim SO, Park SG, Yoo JH, Park YM, Kim HJ,
Jang KT, Cho JW, et al: Expression of heat shock proteins (HSP27,
HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related
hepatocellular carcinomas and dysplastic nodules. World J
Gastroenterol. 11:2072–2079. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Misra UK, Deedwania R and Pizzo SV:
Binding of activated α2-macroglobulin to its cell surface receptor
GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent
activation of LIMK. J Biol Chem. 280:26278–26286. 2005.
|
|
41
|
Shani G, Fischer WH, Justice NJ, Kelber
JA, Vale W and Gray PC: GRP78 and Cripto form a complex at the cell
surface and collaborate to inhibit transforming growth factor β
signaling and enhance cell growth. Mol Cell Biol. 28:666–677.
2008.PubMed/NCBI
|
|
42
|
Al-Hashimi AA, Caldwell J, Gonzalez-Gronow
M, Pizzo SV, Aboumrad D, Pozza L, Al-Bayati H, et al: Binding of
anti-GRP78 autoantibodies to cell surface GRP78 increases tissue
factor procoagulant activity via the release of calcium from
endoplasmic reticulum stores. J Biol Chem. 285:28912–28923. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kelber JA, Panopoulos AD, Shani G, Booker
EC, Belmonte JC, Vale WW and Gray PC: Blockade of Cripto binding to
cell surface GRP78 inhibits oncogenic Cripto signaling via
MAPK/PI3K and Smad2/3 pathways. Oncogene. 28:2324–2336. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ni M, Zhang Y and Lee AS: Beyond the
endoplasmic reticulum: atypical GRP78 in cell viability, signalling
and therapeutic targeting. Biochem J. 434:181–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Misra UK and Pizzo AV: Ligation of cell
surface GRP78 with antibody directed against the COOH-terminal
domain of GRP78 suppresses Ras/MAPK and PI3-kinase/AKT signaling
while promoting caspase activation in human prostate cancer cells.
Cancer Biol Ther. 9:1–11. 2010. View Article : Google Scholar
|
|
46
|
Misra UK, Mowery Y, Kaczowka S and Pizzo
SV: Ligation of cancer cell surface GRP78 with antibodies directed
against its COOH-terminal domain up-regulates p53 activity and
promotes apoptosis. Mol Cancer Ther. 8:1350–1362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Backes C, Ludwig N, Leidinger P, Harz C,
Hoffmann J, Keller A, Meese E, et al: Immunogenicity of
autoantigens. BMC Genomics. 12:3402011. View Article : Google Scholar : PubMed/NCBI
|
